Acceleron Pharma Overview
- Year Founded
-
2003
- Status
-
Acquired/Merged
- Employees
-
312
- Latest Deal Type
-
M&A
- Latest Deal Amount
-
$11.5B
- Investors
-
1
Acceleron Pharma General Information
Description
Acceleron Pharma is a biotechnology company focused on the discovery, development, and commercialization of novel therapies. The company's research focuses on key natural regulators of cellular growth and repair. Acceleron generates its revenue through collaboration, licensing, and research arrangements with collaboration partners for the development and commercialization of therapeutic candidates. The company sometimes uses contract research organizations and research institutions outside the United States.
Contact Information
Website
www.acceleronpharma.comCorporate Office
- 128 Sidney Street
- Cambridge, MA 02139
- United States
Corporate Office
- 128 Sidney Street
- Cambridge, MA 02139
- United States
Acceleron Pharma Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 19. Merger/Acquisition | 19-Nov-2021 | $11.5B | Completed | Generating Revenue | ||
| 18. 2PO | 06-Jan-2016 | Completed | Generating Revenue | |||
| 17. Secondary Transaction - Open Market | Completed | Generating Revenue | ||||
| 16. PIPE | 24-Aug-2015 | Completed | Generating Revenue | |||
| 15. PIPE | 24-Sep-2013 | Completed | Clinical Trials - Phase 2 | |||
| 14. IPO | 19-Sep-2013 | Completed | Clinical Trials - Phase 2 | |||
| 13. Debt - General | 01-Jun-2012 | Completed | Clinical Trials - Phase 2 | |||
| 12. Later Stage VC (Series F) | 23-Dec-2011 | Completed | Clinical Trials - Phase 2 | |||
| 11. Grant | 06-Jan-2011 | $1.5M | $137M | Completed | Clinical Trials - Phase 2 | |
| 10. Later Stage VC (Series E) | 18-Jun-2010 | $8.35M | $137M | Completed | Clinical Trials - Phase 2 |
Acceleron Pharma Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series F | ||||||||
| Series E | ||||||||
| Series D1 | ||||||||
| Series D | ||||||||
| Series C1 | ||||||||
| Series C | ||||||||
| Series B | 16,944,378 | $0.001000 | 8% | $1.85 | $1.85 | 1x | $1.85 | 16.6% |
| Series A | 26,069,980 | $0.001000 | 8% | $1 | $1 | 1x | $1 | 25.54% |
Acceleron Pharma Comparisons
Industry
Financing
Details
Acceleron Pharma Competitors (74)
One of Acceleron Pharma’s 74 competitors is Protagonist Therapeutics, a Formerly VC-backed company based in Newark, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Protagonist Therapeutics | Formerly VC-backed | Newark, CA | ||||
| Genfit | Formerly VC-backed | Loos, France | ||||
| Verve Therapeutics | Formerly VC-backed | Boston, MA | ||||
| Idorsia Pharmaceuticals | Corporation | Allschwil, Switzerland | ||||
| Bicycle Therapeutics | Formerly VC-backed | Cambridge, United Kingdom |
Acceleron Pharma Patents
Acceleron Pharma Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20260132207-A1 | Activin type 2 receptor binding proteins and uses thereof | Pending | 31-Jul-2025 | ||
| US-20230398181-A1 | Treatments for complications associated with chronic liver disease | Pending | 08-Jun-2022 | ||
| US-20230398182-A1 | Treatments for hermansky-pudlak syndrome | Pending | 08-Jun-2022 | ||
| EP-4387647-A2 | Compositions and methods for treating renal diseases or conditions | Pending | 16-Aug-2021 | ||
| EP-4387647-A4 | Compositions and methods for treating renal diseases or conditions | Pending | 16-Aug-2021 | A61K38/179 |
Acceleron Pharma Signals
Acceleron Pharma Former Investors (17)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Advanced Technology Ventures | Venture Capital | Minority | ||
| Alkermes | Corporation | Minority | ||
| Avalon Ventures | Venture Capital | Minority | ||
| Bessemer Venture Partners | Venture Capital | Minority | ||
| Bock Family Ventures | Venture Capital | Minority |
Acceleron Pharma ESG
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
Rank
Percentile
Pharmaceuticals
Industry
Rank
Percentile
Biotechnology
Subindustry
Rank
Percentile
Acceleron Pharma FAQs
-
When was Acceleron Pharma founded?
Acceleron Pharma was founded in 2003.
-
Where is Acceleron Pharma headquartered?
Acceleron Pharma is headquartered in Cambridge, MA.
-
What is the size of Acceleron Pharma?
Acceleron Pharma has 312 total employees.
-
What industry is Acceleron Pharma in?
Acceleron Pharma’s primary industry is Drug Discovery.
-
Is Acceleron Pharma a private or public company?
Acceleron Pharma is a Private company.
-
What is the current valuation of Acceleron Pharma?
The current valuation of Acceleron Pharma is .
-
What is Acceleron Pharma’s current revenue?
The current revenue for Acceleron Pharma is .
-
How much funding has Acceleron Pharma raised over time?
Acceleron Pharma has raised $425M.
-
Who are Acceleron Pharma’s investors?
Advanced Technology Ventures, Alkermes, Avalon Ventures, Bessemer Venture Partners, and Bock Family Ventures are 5 of 17 investors who have invested in Acceleron Pharma.
-
Who are Acceleron Pharma’s competitors?
Protagonist Therapeutics, Genfit, Verve Therapeutics, Idorsia Pharmaceuticals, and Bicycle Therapeutics are some of the 74 competitors of Acceleron Pharma.
-
When was Acceleron Pharma acquired?
Acceleron Pharma was acquired on 19-Nov-2021.
-
Who acquired Acceleron Pharma?
Acceleron Pharma was acquired by Merck & Co..
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process